ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Unsupervised Deep Representation Learning and Probabilistic Clustering for the Systems-Level Discovery of Germline Mutation Signatures in Pediatric Cancers.Biomedicines · 2026Article
- Immunotherapy resistance in colorectal cancer: therapeutic strategies and biomarker-guided approaches.Cancer cell international · 2026Review
- Immune checkpoint inhibitors in dMMR-MSI-H colorectal cancer: rationale, progress and prospects.Frontiers in immunology · 2026Review
- Development and validation of an interpretable prediction model using spatial patterns of tumor-infiltrating lymphocytes in H&E-stained whole-slide images for immune subtyping of lung adenocarcinoma.Frontiers in immunology · 2026Article
- Pairwise ratio transformation of gene expression data leads to improved checkpoint response prediction in lung cancer patients.BMC bioinformatics · 2025Article
- Genome instability and crosstalk with the immune response.Genome medicine · 2025Review
- A field resource for the glioma cerebrospinal fluid proteome: Impacts of resection and location on biomarker discovery.Neuro-oncology · 2025Article
- Refractory Burkitt Lymphoma Following Acute Lymphoblastic Leukemia in a Patient with HomozygousTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024Article
- Comparison of standard mismatch repair deficiency and microsatellite instability tests in a large cancer series.Journal of translational medicine · 2024Article
- Unlocking the potential of immunotherapy in platinum-resistant ovarian cancer: rationale, challenges, and novel strategies.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Complete response of a locally advanced pulmonary hepatoid adenocarcinoma patient to perioperative XELOX-containing chemoimmunotherapy.Genes & diseases · 2024Article
- Progresses in biomarkers for cancer immunotherapy.MedComm · 2023Review
- Genomic and Phenotypic Biomarkers for Precision Medicine Guidance in Advanced Prostate Cancer.Current treatment options in oncology · 2023Review
- Nanomedicines: intervention in inflammatory pathways of cancer.Inflammopharmacology · 2023Review
- MLH1 Loss in Primary Prostate Cancer.JCO precision oncology · 2023Article
- ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma.BMC pulmonary medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Mutational burden is positively correlated with tumor neoantigen load and studies have demonstrated an association between high tumor mutational burden (TMB) and response to checkpoint blockade. On the basis of a phase II study, the anti-PD-1 therapy, pembrolizumab, was given FDA approval for use in any solid tumor with a high TMB (i.e., >10 mutations/megabase) as assessed by the FoundationOne companion diagnostic. This was an important step in expanding a potentially efficacious treatment option to patients who are likely to benefit and have limited other therapies available. Following this approval, there has been debate regarding the wide applicability of this approval and the most appropriate use of TMB as a predictive biomarker, with several studies questioning the predictive utility of TMB in this context. We discuss the scientific rationale and utility of using TMB as a tool to predict response to immunotherapy as well as address this biomarker's limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.